Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients.

MLA

Morrison, Gladys, et al. “Utility of Patient-Derived Lymphoblastoid Cell Lines as an Ex Vivo Capecitabine Sensitivity Prediction Model for Breast Cancer Patients.” Oncotarget, 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1367413267&authtype=sso&custid=ns315887.

APA

Morrison, G., Morrison, G., Lenkala, D., LaCroix, B., Ziliak, D., Abramson, V., Morrow, P. K., Forero, A., Van Poznak, C., Rugo, H. S., Nanda, R., O’Donnell, P. H., & Huang, R. S. (2016). Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget.

Chicago

Morrison, Gladys, Gladys Morrison, Divya Lenkala, Bonnie LaCroix, Dana Ziliak, Vandana Abramson, Phuong Khanh Morrow, et al. 2016. “Utility of Patient-Derived Lymphoblastoid Cell Lines as an Ex Vivo Capecitabine Sensitivity Prediction Model for Breast Cancer Patients.” Oncotarget. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1367413267&authtype=sso&custid=ns315887.